Oral Complement Factor D Inhibitor for Geographic Atrophy Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for geographic atrophy secondary to age-related macular degeneration (AMD) lack effective options, with no approved therapies available, and existing treatments often require invasive intravitreal injections, posing challenges in accessibility and safety.

Innovation Solution

The use of a small molecule complement factor D inhibitor, Compound 1 (ALXN2040 or danicopan), administered orally, which selectively targets melanin-containing ocular tissues and crosses the blood-retina barrier, providing a convenient and systemic treatment option that reduces the risk of ocular injection-related adverse events.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If intravitreal injections are used to treat geographic atrophy, then local delivery to the eye is achieved, but patient compliance deteriorates and risk of ocular injection-related adverse events increases

Engineering Contradiction:

Improveefficacy of treatmentVSAvoidpatient compliance

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent replaces the mechanical intravitreal injection system with an oral pharmacological system. Compound 1 is administered orally as a small molecule inhibitor that systemically distributes to the eye, eliminating the need for mechanical needle injection while maintaining therapeutic efficacy through oral bioavailability and ocular tissue penetration.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces blood as an intermediary delivery system. Instead of direct intravitreal injection, Compound 1 is delivered systemically through the bloodstream, which then distributes the drug to ocular tissues including the retina and choroid, where it exerts its protective effect against geographic atrophy progression.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If intravitreal injections are used to treat geographic atrophy, then direct delivery to the retina is achieved, but risk of ocular injection-related adverse events increases

Engineering Contradiction:

Improveefficacy of treatmentVSAvoidocular injection-related adverse events

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent converts the potentially harmful systemic circulation into a beneficial delivery mechanism. By designing Compound 1 as an orally available small molecule with appropriate pharmacokinetic properties, the systemic circulation becomes a useful pathway for delivering the drug to ocular tissues, avoiding the local trauma of injections while achieving therapeutic concentrations in the eye.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

3Ease of operation

If oral administration is used, then patient compliance and safety are improved, but selective retention in ocular tissues must be achieved

Engineering Contradiction:

Improvepatient complianceVSAvoidselective retention in ocular tissues

Core Design Contradiction:

Ease of operationVSQuantity of substance

Solution Approach 1:

The patent applies local quality by designing Compound 1 with specific molecular properties that enable selective accumulation in ocular tissues. The compound exhibits preferential retention in the retina and choroid compared to other tissues, achieving local concentration enhancement through its chemical structure and pharmacokinetic characteristics despite oral administration.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent utilizes parameter changes in the pharmacokinetic profile of Compound 1, specifically its oral bioavailability, tissue distribution patterns, and retention characteristics. By optimizing these parameters, the compound achieves sufficient and selective concentrations in ocular tissues following oral administration, balancing systemic availability with local tissue specificity.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Compound 1 effectively slows or reverses the progression of geographic atrophy by reducing the mean rate of increase in total GA lesion area, improving visual acuity, and enhancing clinical outcomes with improved patient compliance and reduced adverse events.

Implementation Method 1

the ability of Compound 1 to cross the blood-retina barrier

Methodology Applied

Scientific EffectPassive diffusion: Diffusion

Implementation Method 2

targeted delivery to the retina and choroid through selective binding to melanin-containing ocular tissues

Methodology Applied

Scientific EffectMolecular binding: Adsorption

Data Source

PatentUS20240252497A1Use of complement factor d inhibitor for treatment of geographic atrophy secondary to age-related macular degeneration

Publication Date: 2024.08.01 ALEXION PHARMACEUTICALS INC

AI summary

Disclosed herein are methods for treating geographic atrophy secondary to age-related macular degeneration (AMD) and intermediate AMD in a subject. The methods include administering to the subject a therapeutically effective amount of a small molecule complement factor D inhibitor.